DiThera’s proprietary Nucleic Acid Directed Protein Complementation (NadPC) platform technology is a novel means by which to visualize and influence nucleic acid expression in live cells. Since NadPC targets the underlying driver of cell biology and disease – DNA and RNA – the technology is amenable to personalized medicine for diseases such as cancer.
NadPC also has potential applications to a wide variety of basic research and biomedical applications including therapeutics, imaging, and diagnostics.
Job Openings
No current openings